Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45


Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network..

Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.


Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.

Yang J, Liao D, Wang Z, Liu F, Wu G.

J Surg Res. 2011 Jun 1;168(1):97-102. doi: 10.1016/j.jss.2009.06.025. Epub 2009 Jul 18.


Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E.

PLoS One. 2009 Nov 13;4(11):e7752. doi: 10.1371/journal.pone.0007752.


Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels.

Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW, Wong J, Gage C, Furmaga WB, Redding SW, McDevitt JT.

Biosens Bioelectron. 2009 Aug 15;24(12):3622-9. doi: 10.1016/j.bios.2009.05.026. Epub 2009 May 27.


Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.

Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW.

Nat Med. 2009 May;15(5):566-71. doi: 10.1038/nm.1903. Epub 2009 Apr 12.


Neurosphere formation is an independent predictor of clinical outcome in malignant glioma.

Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI.

Stem Cells. 2009 Apr;27(4):980-7. doi: 10.1002/stem.15.


PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.

Brachmann S, Fritsch C, Maira SM, García-Echeverría C.

Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/ Epub 2009 Feb 7. Review.


An integrated microfluidic culture device for quantitative analysis of human embryonic stem cells.

Kamei K, Guo S, Yu ZT, Takahashi H, Gschweng E, Suh C, Wang X, Tang J, McLaughlin J, Witte ON, Lee KB, Tseng HR.

Lab Chip. 2009 Feb 21;9(4):555-63. doi: 10.1039/b809105f. Epub 2008 Nov 20.


Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood.

Fan R, Vermesh O, Srivastava A, Yen BK, Qin L, Ahmad H, Kwong GA, Liu CC, Gould J, Hood L, Heath JR.

Nat Biotechnol. 2008 Dec;26(12):1373-8. doi: 10.1038/nbt.1507. Epub 2008 Nov 16.


High content cell screening in a microfluidic device.

Cheong R, Wang CJ, Levchenko A.

Mol Cell Proteomics. 2009 Mar;8(3):433-42. doi: 10.1074/mcp.M800291-MCP200. Epub 2008 Oct 24.


Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML.

Cancer Cell. 2008 Oct 7;14(4):335-43. doi: 10.1016/j.ccr.2008.08.014.


Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis.

Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR.

Nat Biotechnol. 2008 Sep;26(9):1019-27. doi: 10.1038/nbt.1490.


Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME.

J Clin Oncol. 2008 Jun 20;26(18):3015-24. doi: 10.1200/JCO.2007.15.7164.


Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.


Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK.

Genes Dev. 2007 Nov 1;21(21):2683-710. Review.


Nanotechnology and cancer.

Heath JR, Davis ME.

Annu Rev Med. 2008;59:251-65. Review.


Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.

Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72. Epub 2007 Jul 23.


Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.

VanDijken J, Kaigala GV, Lauzon J, Atrazhev A, Adamia S, Taylor BJ, Reiman T, Belch AR, Backhouse CJ, Pilarski LM.

J Mol Diagn. 2007 Jul;9(3):358-67.


PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.

Mellinghoff IK, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81. Review.


Single-cell quantification of molecules and rates using open-source microscope-based cytometry.

Gordon A, Colman-Lerner A, Chin TE, Benjamin KR, Yu RC, Brent R.

Nat Methods. 2007 Feb;4(2):175-81. Epub 2007 Jan 21.


Supplemental Content

Support Center